To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder Cancer

Jeffrey Holzbeierlein, M.D.
Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.
Johnathan E. Rosenberg, M.D.
Jonathan E. Rosenberg, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Diane Zipursky Quale
Diane Zipursky Quale, co-founder of the Bladder Cancer Advocacy Network, discusses the importance of patients discussing their treatment options with their physician before undergoing surgery.
Jason Harris
For patients with cisplatin-ineligible advanced urothelial cancer, frontline treatment with Keytruda (pembrolizumab) showed long-lasting response, according to updated phase 2 results from the KEYNOTE-052 trial.
Shannon Connelly
Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.
Ariela Katz
When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.
Katie Kosko
Combined modality treatment (CMT) could be considered a first course of treatment for patients with muscle-invasive bladder cancer, according to the authors of a recent study published in the International Journal of Radiation Oncology.
Jason M. Broderick
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
Jason Harris
According to results from the phase 3 RANGE trial, the addition of Cyramza (ramucirumab) to docetaxel resulted in improved progression-free survival for patients with previously treated locally advanced or unresectable or metastatic urothelial carcinoma.
Brielle Urciuoli
Actress Marilu Henner spoke with CURE about her husband's journey with cancer and the importance of having the difficult conversations.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable